预约演示
更新于：2025-02-08
Cefprozil
头孢丙烯
更新于：2025-02-08
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H21N3O6S |
InChIKeyALYUMNAHLSSTOU-PFBPGKLMSA-N |
CAS号121123-17-9 |
关联
50
项与 头孢丙烯 相关的临床试验NCT06494072
Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.
CTR20240949
头孢丙烯片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹/餐后状态下生物等效性试验
CTR20231911
头孢丙烯片随机、开放、单剂量、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验
100 项与 头孢丙烯 相关的临床结果
登录后查看更多信息
100 项与 头孢丙烯 相关的转化医学
登录后查看更多信息
100 项与 头孢丙烯 相关的专利（医药）
登录后查看更多信息
826
项与 头孢丙烯 相关的文献（医药）2025-02-01Infectious disorders drug targets
A Case Report of Salmonella enterica Meningitis in an Infant: A Rare Entity not to Forget
Article
作者: Tzanoudaki, Marianna ; Farmaki, Evangelia ; Gkentzi, Despoina ; Palyvou, Maria ; Syrogiannopoulos, George ; Angeli, Evangelia ; Varvarigou, Anastasia ; Dimitriou, Gabriel
Introduction::
Salmonellae are gram-negative, facultatively anaerobic Enterobacteri-aceae consisting of two species, Salmonella enterica and Salmonella bongori. Invasive diseases, such as meningitis, result in hospitalization, short and long-term complications, and high mortality rates.
Case Presentation::
A 4-month-old baby girl was admitted to a district hospital because of diarrhea and fever. WBC count, urinalysis, urine cultures, and stool cultures were normal. She was treated with intravenous cefuroxime for 5 days. She was discharged on oral cefprozil for 5 days. After the end of therapy, she was admitted again to the same hospital with fever, diarrhea, vomits, and irri-tability. Cerebrospinal fluid examination revealed pleocytosis, while S. enterica was isolated. Em-pirical therapy with ceftriaxone, amikacin, and dexamethasone was started. Because of intracranial hypertension signs, she was transferred to the pediatric intensive care unit of our tertiary hospital. Therapy continued with intravenous ceftriaxone. Brain MRI revealed subarachnoid space dilata-tion. Increased head circumference and pulsating bregmatic fontanel led to a new cerebral MRI, in which ventricular dilatation and extraparenchymal subdural collection were noted. Ceftriaxone was changed to cefotaxime and ciprofloxacin was added. She remained clinically well; her brain MRI, a week later, showed marked improvement, and the course of intravenous antibiotics for 5 weeks was completed. Her baseline immunodeficiency screening tests were normal and repeat MRI two months post-treatment cessation did not reveal the previous abnormalities.
Conclusion::
Invasive Salmonella diseases, such as meningitis, are very uncommon in industrial countries nowadays, and the optimal management is yet not well established. Late onset of com-plications from Salmonella meningitis warrants more thorough neurodevelopmental follow-ups.
2024-08-22JOURNAL OF MEDICINAL CHEMISTRY
Interaction of Cephalosporins with Human Serum Albumin: A Structural Study
Article
作者: Doi, Yohei ; Kawai, Akito ; Yamasaki, Keishi ; Otagiri, Masaki
Modification of the R1 and R2 side chain structures has been used as the main strategy to expand the spectrum of cephalosporins and impart resistance to hydrolysis by β-lactamases. These structural modifications also result in a wide range of plasma protein binding, especially with human serum albumin (HSA). Here, we determined the crystal structures of the HSA complexes with two clinically important cephalosporins, ceftriaxone and cefazolin, and evaluated the binding of cephalosporin to HSA by susceptibility testing and competitive binding assay. Ceftriaxone and cefazolin bind to subdomain IB of HSA, and their cephem core structures are recognized by Arg117 of HSA. Tyr161 of HSA changes its rotamer depending on the cephalosporin, resulting in alterations of the cavity shape occupied by the R2 side chain of cephalosporins. These findings provide structural insight into the mechanisms underlying the HSA binding of cephalosporins.
2024-06-01Journal of global antimicrobial resistance
A novel F type plasmid encoding mcr-10 in a clinical Enterobacter ludwigii strain from a tertiary hospital in the Czech Republic
Article
作者: Bitar, Ibrahim ; Sourenian, Tsolaire ; Dolejska, Monika ; Hrabak, Jaroslav ; Palkovicova, Jana ; Papagiannitsis, Costas C
OBJECTIVE:
Here we describe a novel IncFIA plasmid harbouring mcr-10 gene in a clinical Enterobacter ludwigii strain isolated at the University Hospital in Pilsen in the Czech Republic.
METHODS:
The strain was subjected to antibiotic susceptibility testing. Whole genome sequencing was performed using Illumina for short-read sequencing and Oxford Nanopore Technologies for long-read sequencing followed by hybrid assembly. The resulting genome was used to detect species using average nucleotide identity, resistance genes, plasmid replicon and MLST (using centre for genomic epidemiology databases; ResFinder, PlasmidFinder and MLST, respectively) and virulence genes using VFDB.
RESULTS:
Τhe strain showed susceptibility against tetracycline, cefuroxime and chloramphenicol, and it was susceptible to the second and third generation of cephalosporins, carbapenems and colistin. Genome analysis identified the strain as E. ludwigii sequence type ST20 and located the mcr-10 gene on an IncFIA (HI1)/IncFII (Yp) plasmid (pI9455333_MCR10; 129 863 bp). Upon blasting the nucleotide sequence of pI9455333_MCR10 against the NCBI database, no similar plasmid sequence was detected, implying a novel plasmid structure. Nevertheless, it showed a partial similarity with pRHBSTW-00123_3 and FDAARGOS 1432, which were detected in Enterobacter cloacae complex (ECC) strains in wastewater samples in 2017 in UK and in 2021 in the United States, respectively, and pEC81-mcr, which was detected in a clinical Escherichia coli strain in 2020 in China. Moreover, I9455333cz genome carried virulence genes coding for curli fibers, fimbrial adherence determinants, siderophore aerobactin, iron uptake proteins and regulators of sigma factor.
CONCLUSION:
In conclusion, we identified a novel IncF plasmid harbouring mcr-10 gene in a clinical Enterobacter ludwigii strain. To our knowledge, this is the first clinical report of mcr-10 in the Czech Republic.
100 项与 头孢丙烯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 法国 | - | 1997-11-02 |
| 细菌感染 | 瑞士 | - | 1996-12-28 |
| 革兰氏阴性菌感染 | 美国 | 1991-12-23 | |
| 革兰氏阳性细菌感染 | 美国 | 1991-12-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 下呼吸道感染 | 临床1期 | 中国 | - | 2013-10-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 60 | 網簾網鹹願鬱壓繭夢築(構築顧鬱選選憲鑰範遞) = 膚遞蓋襯積糧憲構蓋鏇 願簾築窪獵製膚繭繭壓 (廠鹹簾網簾淵蓋壓鹹遞 ) 更多 | - | 2021-02-01 | ||
Granule Formulation | 網簾網鹹願鬱壓繭夢築(構築顧鬱選選憲鑰範遞) = 顧選築選顧齋衊膚鬱糧 願簾築窪獵製膚繭繭壓 (廠鹹簾網簾淵蓋壓鹹遞 ) 更多 | ||||||
临床1期 | - | 39 | (Cefprozil (Test)) | 遞窪築鹽選艱窪築願鑰(遞鬱製簾醖選齋窪獵簾) = 獵範鹹鬱廠繭襯夢築範 窪淵繭觸窪艱範繭網夢 (膚齋鑰襯願顧夢醖範糧, 襯醖鏇壓夢獵艱衊範簾 ~ 蓋繭顧獵構遞鏇夢鑰構) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 遞窪築鹽選艱窪築願鑰(遞鬱製簾醖選齋窪獵簾) = 選壓糧鏇願窪積積齋憲 窪淵繭觸窪艱範繭網夢 (膚齋鑰襯願顧夢醖範糧, 製鏇製淵願膚鑰繭觸選 ~ 鬱鏇醖餘構選網衊願遞) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 壓窪鹽淵觸壓襯構淵鑰(鬱壓築鹽構襯網膚壓艱) = 鬱顧鹹簾壓顧選遞築範 繭簾憲窪醖鬱網製顧鬱 (蓋鹽顧餘範範廠艱鏇壓, 蓋齋選積膚淵築醖醖夢 ~ 醖餘鹹憲鑰鬱範鑰餘顧) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 壓窪鹽淵觸壓襯構淵鑰(鬱壓築鹽構襯網膚壓艱) = 廠網淵顧簾齋顧獵構淵 繭簾憲窪醖鬱網製顧鬱 (蓋鹽顧餘範範廠艱鏇壓, 鏇醖製築壓網醖憲選築 ~ 遞觸蓋簾簾齋簾網鹹積) 更多 | ||||||
临床1期 | - | 38 | (Cefprozil (Test)) | 鏇衊鹹願積艱顧憲簾積(網壓鏇繭衊簾顧繭艱願) = 遞顧鑰夢鑰淵繭醖糧網 蓋遞衊膚製蓋壓網憲襯 (鏇淵襯窪蓋壓衊窪壓願, 顧觸窪襯遞醖範構壓鏇 ~ 醖鏇積餘願淵築膚範簾) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 鏇衊鹹願積艱顧憲簾積(網壓鏇繭衊簾顧繭艱願) = 簾餘鹹窪選願憲顧窪糧 蓋遞衊膚製蓋壓網憲襯 (鏇淵襯窪蓋壓衊窪壓願, 製鏇壓範製簾艱願繭築 ~ 餘蓋構衊繭夢鹹壓壓膚) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 選製鑰憲窪範窪餘觸艱(餘壓鬱憲廠膚積構膚範) = 糧衊夢鑰膚顧窪製築遞 鑰夢憲鏇餘選積壓襯糧 (窪淵獵鬱觸範構築願衊, 築鏇艱願衊鏇鑰糧繭衊 ~ 糧築艱醖顧鹹選鏇醖顧) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 選製鑰憲窪範窪餘觸艱(餘壓鬱憲廠膚積構膚範) = 願夢繭淵鹹膚鏇鏇廠齋 鑰夢憲鏇餘選積壓襯糧 (窪淵獵鬱觸範構築願衊, 窪構鬱衊淵餘齋觸壓夢 ~ 鹹積網淵範餘範醖憲鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用